Softw 82 , (2017)
Medication program persistence and engagement: January 2026 analysis of 30,239 Noom GLP-1 Rx Program members who started a GLP-1Rx plan between December 2024 and February 2025, evaluating program persistence by engagement quartile
See your appeal options Your GLP-1 coverage, denied approved Honest Care helps patients fight back: Free Templates Premium Support Available I was denied coverage for
Use of Ozempic, a GLP-1 medication approved by the Food and Drug Administration (FDA) to treat diabetes, is increasing 75% (or $6.7 billion in spending) on a rolling 12-month average.1 This type of snowballing drug spend, if left unchecked, can cause plan premiums to soar, potentially pricing out members, leaving people who need drug coverage without the ability to pay for it
Forty-two percent of those who were currently using GLP-1s said losing weight on these medications requires the same willpower as traditional methods, and 15% said it takes even more